China launched a five-year medical research programme on the blood pressure control target for adults with type 2 diabetes to reduce cardiovascular and death risks.
More than 200 research centres across the country will participate in the programme, launched in Chongqing in southwest China.
Researchers will randomly compare clinical trials of 12,000 type 2 diabetic patients to find the optimal blood pressure control target, said Ning Guang, a Chinese Academy of Engineering Academician and Research Initiator.
“We know that lowering blood pressure is critical for the treatment of diabetes, but it is still not clear how much to reduce it,” Ning said.
Ning noted that internationally, there is no standard anti-hypertension target.
Statistics show that China has 114 million adult diabetic patients, with more than half suffering from combined hypertension.
Compared with those, who have no elevated blood pressure, they have higher risks of myocardial infarction, stroke, as well as eyeground, renal and neurological complications.